CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 256 enrolled
Drug / intervention
NIATx Coaching +1 morebehavioral
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04363320
NCT04363320N/ACompleted
CompareCT.gov

Fostering MAT Use in Justice Populations

University of Wisconsin, Madison·interventional·Posted Apr 27, 2020·Updated May 28, 2025

In Brief

A clinical study evaluating NIATx Coaching and ECHO for Opioid-use Disorder and Recidivism. Completed, enrolled 256 participants across 1 site.

Detailed Summary

The grant will test two timely and successful evidence-based implementation practices, NIATx Coaching and ECHO, with jail/community-based healthcare providers to increase medication assisted treatment (MAT) use with justice populations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-use Disorder, Recidivism
CountriesUnited States
CollaboratorsGeorge Mason University, National Institute on Drug Abuse (NIDA)

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedApr 27, 2020
Enrollment StartJul 30, 2020
Primary CompletionFeb 28, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.2 years ago

Interventions

NIATx Coachingbehavioral

NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.

ECHObehavioral

The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.